Evidence map›Paper›PMID 34670568›Full record

ArticleMolecular cancer2021

Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression.

Lindsay S Cooley, Justine Rudewicz, Wilfried Souleyreau, Andrea Emanuelli, Arturo Alvarez-Arenas, Kim Clarke, Francesco Falciani, Maeva Dufies, Diether Lambrechts, Elodie Modave and 11 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 5 countries.

Lindsay S Cooley *University of Bordeaux, LAMC, Pessac, France.
Justine Rudewicz *University of Bordeaux, LAMC, Pessac, France.
Wilfried Souleyreau *University of Bordeaux, LAMC, Pessac, France.
Andrea Emanuelli *University of Bordeaux, LAMC, Pessac, France.
Arturo Alvarez-ArenasMathematical Modeling for Oncology Team, Inria Bordeaux Sud-Ouest, Talence, France.
Kim ClarkeUniversity of Liverpool, Institute of Systems, Molecular and Integrative Biology, Liverpool, UK.
Francesco FalcianiUniversity of Liverpool, Institute of Systems, Molecular and Integrative Biology, Liverpool, UK.
Maeva DufiesCentre Scientifique de Monaco, Biomedical Department, Principality of Monaco, Monaco.
Diether LambrechtsVIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.
Elodie ModaveVIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.
Domitille Chalopin-FillotBordeaux Bioinformatics Center, CBiB, University of Bordeaux, Bordeaux, France.
Raphael PineauUniversity of Bordeaux, "Service Commun des Animaleries", Bordeaux, France.
Damien AmbrosettiCentre Hospitalier Universitaire (CHU) de Nice, Hôpital Pasteur, Central laboratory of Pathology, Nice, France.
Jean-Christophe BernhardCentre Hospitalier Universitaire (CHU) de Bordeaux, service d'urologie, Bordeaux, France.
Alain RavaudCentre Hospitalier Universitaire (CHU) de Bordeaux, service d'oncologie médicale, Bordeaux, France.
Sylvie NégrierUniversité de Lyon, Centre Léon Bérard, Lyon, France.
Jean-Marc FerreroCentre Antoine Lacassagne, Clinical Research Department, Nice, France.
Gilles PagèsCentre Scientifique de Monaco, Biomedical Department, Principality of Monaco, Monaco.
Sebastien BenzekryMathematical Modeling for Oncology Team, Inria Bordeaux Sud-Ouest, Talence, France.
Macha NikolskiBordeaux Bioinformatics Center, CBiB, University of Bordeaux, Bordeaux, France.
Andreas BikfalviUniversity of Bordeaux, LAMC, Pessac, France. andreas.bikfalvi@u-bordeaux.fr.ORCID 0000-0003-4138-5229
Université de Bordeaux · FRCentre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Bordeaux · FRUniversity of Liverpool · GBVIB-KU Leuven Center for Cancer Biology · BECentre Antoine Lacassagne · FRCentre Hospitalier Universitaire de Nice · FRCentre Inria de l'université de Bordeaux · FRUniversité Claude Bernard Lyon 1 · FR

Funding

institut national du cancer SIRIC Brio Commucanjunta de comunidades de castilla-la mancha SBPLY/19/180501/000211plan cancer C18005GS, SystemsRCCrégion nouvelle aquitaine Post-doctoral fellowshipuniversity of bordeaux G2P project
6 · The paper itself

Abstract

backgroundRenal Cell Carcinoma (RCC) is difficult to treat with 5-year survival rate of 10% in metastatic patients. Main reasons of therapy failure are lack of validated biomarkers and scarce knowledge of the biological processes occurring during RCC progression. Thus, the investigation of mechanisms regulating RCC progression is fundamental to improve RCC therapy.

methodsIn order to identify molecular markers and gene processes involved in the steps of RCC progression, we generated several cell lines of higher aggressiveness by serially passaging mouse renal cancer RENCA cells in mice and, concomitantly, performed functional genomics analysis of the cells. Multiple cell lines depicting the major steps of tumor progression (including primary tumor growth, survival in the blood circulation and metastatic spread) were generated and analyzed by large-scale transcriptome, genome and methylome analyses. Furthermore, we performed clinical correlations of our datasets. Finally we conducted a computational analysis for predicting the time to relapse based on our molecular data.

resultsThrough in vivo passaging, RENCA cells showed increased aggressiveness by reducing mice survival, enhancing primary tumor growth and lung metastases formation. In addition, transcriptome and methylome analyses showed distinct clustering of the cell lines without genomic variation. Distinct signatures of tumor aggressiveness were revealed and validated in different patient cohorts. In particular, we identified SAA2 and CFB as soluble prognostic and predictive biomarkers of the therapeutic response. Machine learning and mathematical modeling confirmed the importance of CFB and SAA2 together, which had the highest impact on distant metastasis-free survival. From these data sets, a computational model predicting tumor progression and relapse was developed and validated. These results are of great translational significance.

conclusionA combination of experimental and mathematical modeling was able to generate meaningful data for the prediction of the clinical evolution of RCC.

Indexed as

Biomarkers, TumorDisease SusceptibilityModels, BiologicalAnimalsCarcinoma, Renal CellCell Line, TumorComputational BiologyDisease ManagementDisease Models, AnimalGene Expression ProfilingGene OntologyGenomicsHeterograftsHumansKidney NeoplasmsMiceBiomarkers, TumorCFBComputational modelMetastasisPrognostic markers renal cell carcinomaSAA2Systems biology approachTumor model

Identifiers

PMID34670568
PMCPMC8527701
OpenAlexW3206101222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.